Cefpirome

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Cefpirome
Accession Number
DB13682
Type
Small Molecule
Groups
Approved
Description
Not Available
Structure
Thumb
Synonyms
  • cefpiroma
  • cefpiromum
External IDs
HR 810
Product Ingredients
IngredientUNIICASInChI Key
Cefpirome sulfateBA5ALU2ZT998753-19-6RKTNPKZEPLCLSF-QHBKFCFHSA-N
Categories
UNII
S72Q2F09HY
CAS number
84957-29-9
Weight
Average: 514.577
Monoisotopic: 514.109309224
Chemical Formula
C22H22N6O5S2
InChI Key
DKOQGJHPHLTOJR-WHRDSVKCSA-N
InChI
InChI=1S/C22H22N6O5S2/c1-33-26-15(13-10-35-22(23)24-13)18(29)25-16-19(30)28-17(21(31)32)12(9-34-20(16)28)8-27-7-3-5-11-4-2-6-14(11)27/h3,5,7,10,16,20H,2,4,6,8-9H2,1H3,(H3-,23,24,25,29,31,32)/b26-15-/t16-,20-/m1/s1
IUPAC Name
1-{[(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}-5H,6H,7H-cyclopenta[b]pyridin-1-ium
SMILES
[H][C@]12SCC(C[N+]3=C4CCCC4=CC=C3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C([O-])=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of bleeding can be increased when Cefpirome is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Cefpirome is combined with (S)-Warfarin.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Cefpirome is combined with 4-hydroxycoumarin.
AbacavirCefpirome may decrease the excretion rate of Abacavir which could result in a higher serum level.
AcarboseCefpirome may decrease the excretion rate of Acarbose which could result in a higher serum level.
AceclofenacCefpirome may decrease the excretion rate of Aceclofenac which could result in a higher serum level.
AcemetacinThe risk or severity of nephrotoxicity can be increased when Cefpirome is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding can be increased when Cefpirome is combined with Acenocoumarol.
AcetaminophenCefpirome may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
Acetylsalicylic acidThe risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Cefpirome.
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0041852
KEGG Drug
D07649
KEGG Compound
C11199
ChemSpider
4586396
ChEBI
3503
ChEMBL
CHEMBL65794
Wikipedia
Cefpirome
ATC Codes
J01DE02 — Cefpirome

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00721 mg/mLALOGPS
logP-1ALOGPS
logP-4ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)2.67ChemAxon
pKa (Strongest Basic)3.54ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area153.92 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity141.3 m3·mol-1ChemAxon
Polarizability50.94 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as cephalosporins. These are compounds containing a 1,2-thiazine fused to a 2-azetidinone to for a oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid moiety or a derivative thereof.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Lactams
Sub Class
Beta lactams
Direct Parent
Cephalosporins
Alternative Parents
N-acyl-alpha amino acids and derivatives / 2,4-disubstituted thiazoles / Pyridinium derivatives / 1,3-thiazines / 2-amino-1,3-thiazoles / Tertiary carboxylic acid amides / Heteroaromatic compounds / Secondary carboxylic acid amides / Amino acids / Azetidines
show 13 more
Substituents
Cephalosporin / N-acyl-alpha amino acid or derivatives / Alpha-amino acid or derivatives / 2,4-disubstituted 1,3-thiazole / Meta-thiazine / Pyridine / 1,3-thiazol-2-amine / Pyridinium / Azole / Heteroaromatic compound
show 28 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
cephalosporin, thiadiazoles, cyclopentapyridine (CHEBI:3503)

Drug created on June 23, 2017 14:46 / Updated on November 02, 2018 09:14